Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Synthetic Biology02:55

Synthetic Biology

4.7K
Synthetic biology is an interdisciplinary science that involves using principles from disciplines such as engineering, molecular biology, cell biology, and systems biology. It involves remodeling existing organisms from nature or constructing completely new synthetic organisms for applications such as protein or enzyme production, bioremediation, value-added macromolecule production, and the addition of desirable traits to crops, to name a few.
Golden rice
Golden rice is a genetically modified...
4.7K
Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

2.5K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.5K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

3.0K
3.0K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Protein-protein Interfaces02:04

Protein-protein Interfaces

12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovation trajectory of Software as a Medical Device: Evidence from the US FDA-approved products.

Digital health·2026
Same author

Strategic pathways of digital health platforms in regulated markets: Evidence from wearable devices.

Digital health·2026
Same author

Real-World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database.

Neuropsychopharmacology reports·2026
Same author

Evolution of the division of labor for First-in-Class Drugs: A Quantitative Analysis of Trends across Company Types, Modalities, and Therapeutic Areas (2012-2024).

Drug discovery today·2026
Same author

[How Can We Overcome the Gap in Social Implementation of Medical Technology (Drug & Digital Device Loss) between Japan and Overseas?]

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2026
Same author

[Current Status of Drug Lag in Rare Disease Treatment and a Multifaceted Approach to Resolving It].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2026

Related Experiment Video

Updated: Jun 3, 2025

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.4K

Multi-layer platform coordination for open innovation in oligonucleotide therapeutics.

Yayoi Kawata1, Taisuke Ichimaru2, Masakazu Kogami2

  • 1Department of Innovation Science, School of Environment and Society, Institute of Science Tokyo, Japan.

Drug Discovery Today
|January 10, 2025
PubMed
Summary

Pharmaceutical companies are using open innovation to develop new oligonucleotide therapeutics. Strategic alliances between biotech, pharma, and CDMOs are crucial for market growth and sustainable drug R&D.

Keywords:
BiopharmaceuticalOligonucleotide therapeuticsOpen innovationPlatform leadershipTechnological transition

More Related Videos

A Multilayer Microfluidic Platform for the Conduction of Prolonged Cell-Free Gene Expression
11:23

A Multilayer Microfluidic Platform for the Conduction of Prolonged Cell-Free Gene Expression

Published on: October 6, 2019

10.1K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.2K

Related Experiment Videos

Last Updated: Jun 3, 2025

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.4K
A Multilayer Microfluidic Platform for the Conduction of Prolonged Cell-Free Gene Expression
11:23

A Multilayer Microfluidic Platform for the Conduction of Prolonged Cell-Free Gene Expression

Published on: October 6, 2019

10.1K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.2K

Area of Science:

  • Pharmaceutical Science
  • Biotechnology
  • Drug Discovery and Development

Background:

  • The pharmaceutical industry faces increasing pressure to innovate due to evolving technologies and diverse medical needs.
  • Oligonucleotide therapeutics represent a new modality requiring novel approaches to research and development (R&D).

Purpose of the Study:

  • To analyze inter-organizational alliances in oligonucleotide therapeutics R&D.
  • To explore the requirements for establishing new markets for novel drug modalities.
  • To understand the dynamics of open innovation in the biopharmaceutical sector.

Main Methods:

  • Analysis of inter-organizational alliances in R&D.
  • Examination of market development stages for oligonucleotide therapeutics.
  • Identification of key players and their roles in different stages of R&D.

Main Results:

  • The oligonucleotide therapeutics market has developed in distinct stages.
  • Open innovation strategies were employed differently across these stages, adapting to technological advancements.
  • Successful market establishment required platform formation: biotech for discovery, pharma for regulatory affairs, and contract development and manufacturing organizations (CDMOs) for manufacturing.

Conclusions:

  • Inter-organizational collaboration is essential for advancing novel drug modalities like oligonucleotide therapeutics.
  • Strategic alliances facilitate market creation and sustainable value generation in pharmaceutical R&D.
  • Understanding the staged development and platform requirements is key for future biopharmaceutical innovation.